Shimosegawa E - Search Results

1

Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with ⁸⁹Zr or ²¹¹At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.

Watabe T, Kabayama K, Naka S, Yamamoto R, Kaneda K, Serada S, Ooe K, Toyoshima A, Wang Y, Haba H, Kurimoto K, Kobayashi T, Shimosegawa E, Tomiyama N, Fukase K, Naka T. Watabe T, et al. Among authors: shimosegawa e. J Nucl Med. 2023 Dec 1;64(12):1949-1955. doi: 10.2967/jnumed.123.266313. J Nucl Med. 2023. PMID: 37827841 Free PMC article.

2

Enhancement of ²¹¹At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid Cancer.

Watabe T, Kaneda-Nakashima K, Liu Y, Shirakami Y, Ooe K, Toyoshima A, Shimosegawa E, Fukuda M, Shinohara A, Hatazawa J. Watabe T, et al. Among authors: shimosegawa e. J Nucl Med. 2019 Sep;60(9):1301-1307. doi: 10.2967/jnumed.118.222638. Epub 2019 Feb 22. J Nucl Med. 2019. PMID: 30796173 Free PMC article.

3

Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: ⁶⁴Cu- and ²²⁵Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models.

Watabe T, Liu Y, Kaneda-Nakashima K, Shirakami Y, Lindner T, Ooe K, Toyoshima A, Nagata K, Shimosegawa E, Haberkorn U, Kratochwil C, Shinohara A, Giesel F, Hatazawa J. Watabe T, et al. Among authors: shimosegawa e. J Nucl Med. 2020 Apr;61(4):563-569. doi: 10.2967/jnumed.119.233122. Epub 2019 Oct 4. J Nucl Med. 2020. PMID: 31586001 Free PMC article.

4

Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.

Yanagawa M, Tatsumi M, Miyata H, Morii E, Tomiyama N, Watabe T, Isohashi K, Kato H, Shimosegawa E, Yamasaki M, Mori M, Doki Y, Hatazawa J. Yanagawa M, et al. Among authors: shimosegawa e. J Nucl Med. 2012 Jun;53(6):872-80. doi: 10.2967/jnumed.111.098699. Epub 2012 May 11. J Nucl Med. 2012. PMID: 22582049 Free article.

5

Practical calculation method to estimate the absolute boron concentration in tissues using ¹⁸F-FBPA PET.

Watabe T, Hanaoka K, Naka S, Kanai Y, Ikeda H, Aoki M, Shimosegawa E, Kirihata M, Hatazawa J. Watabe T, et al. Among authors: shimosegawa e. Ann Nucl Med. 2017 Jul;31(6):481-485. doi: 10.1007/s12149-017-1172-5. Epub 2017 Apr 24. Ann Nucl Med. 2017. PMID: 28439784 Free PMC article.

6

Impact of ¹⁸F-PSMA-1007 Uptake in Prostate Cancer Using Different Peptide Concentrations: Preclinical PET/CT Study on Mice.

Soeda F, Watabe T, Naka S, Liu Y, Horitsugi G, Neels OC, Kopka K, Tatsumi M, Shimosegawa E, Giesel FL, Hatazawa J. Soeda F, et al. Among authors: shimosegawa e. J Nucl Med. 2019 Nov;60(11):1594-1599. doi: 10.2967/jnumed.118.223479. Epub 2019 Mar 22. J Nucl Med. 2019. PMID: 30902876 Free article.

7

Preclinical Evaluation of Radiation-Induced Toxicity in Targeted Alpha Therapy Using [²¹¹At] NaAt in Mice: A Revisit.

Liu Y, Watabe T, Kaneda-Nakashima K, Ooe K, Shirakami Y, Toyoshima A, Shimosegawa E, Nakano T, Shinohara A, Hatazawa J. Liu Y, et al. Among authors: shimosegawa e. Transl Oncol. 2020 Apr;13(4):100757. doi: 10.1016/j.tranon.2020.100757. Epub 2020 Mar 25. Transl Oncol. 2020. PMID: 32220762 Free PMC article.

8

Targeted alpha therapy using astatine (²¹¹At)-labeled phenylalanine: A preclinical study in glioma bearing mice.

Watabe T, Kaneda-Nakashima K, Shirakami Y, Liu Y, Ooe K, Teramoto T, Toyoshima A, Shimosegawa E, Nakano T, Kanai Y, Shinohara A, Hatazawa J. Watabe T, et al. Among authors: shimosegawa e. Oncotarget. 2020 Apr 14;11(15):1388-1398. doi: 10.18632/oncotarget.27552. eCollection 2020 Apr 14. Oncotarget. 2020. PMID: 32341757 Free PMC article.

9

Synthesis of [²¹¹At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution.

Shirakami Y, Watabe T, Obata H, Kaneda K, Ooe K, Liu Y, Teramoto T, Toyoshima A, Shinohara A, Shimosegawa E, Hatazawa J, Fukase K. Shirakami Y, et al. Among authors: shimosegawa e. Sci Rep. 2021 Jun 21;11(1):12982. doi: 10.1038/s41598-021-92476-6. Sci Rep. 2021. PMID: 34155314 Free PMC article.

10

Comparison of the Therapeutic Effects of [²¹¹At]NaAt and [¹³¹I]NaI in an NIS-Expressing Thyroid Cancer Mouse Model.

Watabe T, Liu Y, Kaneda-Nakashima K, Sato T, Shirakami Y, Ooe K, Toyoshima A, Shimosegawa E, Wang Y, Haba H, Nakano T, Shinohara A, Hatazawa J. Watabe T, et al. Among authors: shimosegawa e. Int J Mol Sci. 2022 Aug 21;23(16):9434. doi: 10.3390/ijms23169434. Int J Mol Sci. 2022. PMID: 36012698 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

183 results

Search Page